Green Clinic, Alexandria, Egypt.
Int J Gen Med. 2011 Jan 12;4:45-51. doi: 10.2147/IJGM.S16266.
To study the potential efficacy and tolerability of a natural multiherbal formula (Immumax) containing Echinacea extract 120 mg, garlic powder 100 mg, Nigella sativa oil 200 mg, and Panax ginseng extract 50 mg plus vitamin C 50 mg and elemental zinc 7.5 mg in the treatment of patients suffering from the common cold.
The study was conducted in a prospective, double-blind, randomized, controlled study design in an outpatient setting.
Sixty-two eligible patients with symptoms of the common cold were randomized to either Immumax or placebo treatment groups for the duration of their symptoms or a maximum of 14 days. Resolution rates were estimated using Kaplan-Meier analysis, and resolution profiles were compared between groups using the log-rank test. The mean percentage change in total symptom severity scores at days 4 and 8 from baseline were compared between the two groups by one-way analysis of variance (ANOVA).
The median (interquartile range) time to resolution of all symptoms was 8 (5-9) days in the placebo group and 4 (3-6) days in the Immumax group. The results of the log-rank test indicate that symptoms resolved significantly faster in the Immumax group than in the placebo group (P < 0.001). The mean percentage reduction in total symptom severity scores from baseline at days 4 and 8 was significantly greater in the Immumax group than in the placebo group by one-way ANOVA (P < 0.01).
We can conclude from our study that Immumax is helpful in reducing the duration and severity of common cold symptoms.
研究一种天然多草药配方（Immumax）对感冒患者的潜在疗效和耐受性，该配方含有 120 毫克西洋蒲公英提取物、100 毫克大蒜粉、200 毫克黑种草油和 50 毫克人参提取物以及 50 毫克维生素 C 和 7.5 毫克元素锌。
本研究采用前瞻性、双盲、随机、对照研究设计，在门诊环境中进行。
62 名符合感冒症状的合格患者随机分为 Immumax 或安慰剂治疗组，持续治疗至症状缓解或最长 14 天。采用 Kaplan-Meier 分析估计缓解率，并通过对数秩检验比较组间缓解情况。通过单向方差分析（ANOVA）比较两组患者在第 4 天和第 8 天总症状严重程度评分的平均百分比变化。
安慰剂组所有症状缓解的中位数（四分位距）时间为 8（5-9）天，Immumax 组为 4（3-6）天。对数秩检验结果表明，Immumax 组症状缓解速度明显快于安慰剂组（P <0.001）。在第 4 天和第 8 天，与安慰剂组相比，Immumax 组总症状严重程度评分的平均百分比降低幅度通过单向 ANOVA 显著更大（P <0.01）。
我们可以从我们的研究中得出结论，Immumax 有助于缩短普通感冒症状的持续时间和严重程度。
